Compare GXAI & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GXAI | INBS |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.5M |
| IPO Year | 2022 | 2019 |
| Metric | GXAI | INBS |
|---|---|---|
| Price | $0.77 | $2.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 159.2K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,933,030.00 | ★ $1,980,484.00 |
| Revenue This Year | $271.23 | $778.48 |
| Revenue Next Year | $36.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47901.74 | N/A |
| 52 Week Low | $0.73 | $0.54 |
| 52 Week High | $2.63 | $24.90 |
| Indicator | GXAI | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 49.08 |
| Support Level | $0.75 | $2.26 |
| Resistance Level | $1.30 | $2.45 |
| Average True Range (ATR) | 0.06 | 0.33 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 8.30 | 19.44 |
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.